MAP3K1
MOLECULAR TARGETmitogen-activated protein kinase kinase kinase 1
MAP3K1 (mitogen-activated protein kinase kinase kinase 1) is targeted by 27 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting MAP3K1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | erlotinib | 5.55 | 256 |
| 2 | ponatinib | 4.26 | 70 |
| 3 | ruxolitinib | 4.23 | 68 |
| 4 | bosutinib | 4.08 | 58 |
| 5 | pazopanib | 3.69 | 39 |
| 6 | regorafenib | 3.56 | 34 |
| 7 | baricitinib | 3.56 | 34 |
| 8 | pelitinib | 3.50 | 32 |
| 9 | tae 684 | 3.43 | 30 |
| 10 | ribociclib | 3.26 | 25 |
| 11 | at 9283 | 3.09 | 21 |
| 12 | lestaurtinib | 3.04 | 20 |
| 13 | danusertib | 2.94 | 18 |
| 14 | kw 2449 | 2.64 | 13 |
| 15 | ast 487 | 2.56 | 12 |
| 16 | gsk 461364 | 2.40 | 10 |
| 17 | cudc 101 | 2.40 | 10 |
| 18 | golvatinib | 2.20 | 8 |
| 19 | cyc 116 | 2.08 | 7 |
| 20 | tg100 115 | 2.08 | 7 |
| 21 | rg 547 | 2.08 | 7 |
| 22 | ly 3009120 | 2.08 | 7 |
| 23 | pf 03814735 | 1.79 | 5 |
| 24 | osi 632 | 1.79 | 5 |
| 25 | icotinib | 1.79 | 5 |
| 26 | Crizotinib | 1.10 | 2 |
| 27 | Sorafenib | 0.69 | 1 |
About MAP3K1 as a Drug Target
MAP3K1 (mitogen-activated protein kinase kinase kinase 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 27 compounds with documented MAP3K1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
MAP3K1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.